Indaptus Therapeutics Chief Medical Officer Roger Waltzman, M.D., M.B.A. to Moderate Panel at CMO360 Summit
Dr. Waltzman’s panel, titled “Ensuring Effective and Efficient Trials Through Clinical Operations” will be Monday, April 7 th from 4:05PM – 4:35PM ET.
Yahoo Finance14d
Indaptus Therapeutics Chief Medical Officer Roger Waltzman, M.D., M.B.A. to Moderate Panel at CMO360 Summit
Indaptus Therapeutics NEW YORK, March 25, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company pioneering innovative therapies for cancer and ...
Aktien Check15d
NKGen Biotech To Present Updated Troculeucel Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2025)
SANTA ANA, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and ...
Investing18d
Indaptus reports progress in Decoy20 cancer therapy trial
NEW YORK - Indaptus Therapeutics, Inc. (NASDAQ:INDP), a clinical-stage biotechnology company with a market capitalization of $11.1 million, has shared new pharmacodynamic findings from its ongoing ...
Taiwan News18d
Indaptus Therapeutics Reports New Data Demonstrating Successful Broad Immune System Activation in Weekly Dosing Trial of Decoy20
NEW YORK, March 20, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral infections ...
Benzinga.com18d
Why Plus Therapeutics (PSTV) Shares Are Exploding Higher
Plus Therapeutics shares are trading higher by 244% during Thursday's session. The company announced that the FDA accepted the name REYOBIQ for the company's lead asset. The ‘Trade of the Day ...